6 results about "Human insulin" patented technology

Polypeptide antagonists of the human insulin receptor are provided. In some embodiments, a pharmaceutical formulation is provided, comprising an INSR antagonist as identified herein, and a pharmaceutically acceptable excipient. The formulation may be provided in a unit dose, e.g. a therapeutically effective dose. In methods of the disclosure, an effective dose of a an INSR antagonist as identified herein is administered to an individual having, or at risk of having, hyperinsulinemia, in a dose effective to stabilize, reduce or prevent clinical symptoms of the disease. The individual may be monitored for clinical indicia of disease before, during, and / or after administration.

This invention belongs to the field of stem cell culture medium technology, and provides a cell culture medium for enriching extracellular vesicles derived from stem cells and its preparation method. This invention disperses sodium hyaluronate or sodium hyaluronate-chondroitin sulfate sodium on a defined basic culture medium and grafts porous calcium alginate-gelatin microcarriers onto its surface, while limiting the content of recombinant human insulin, recombinant human transferrin, sodium selenite, and recombinant human serum albumin. This forms a culture system that combines a cell interaction interface with separable microcarriers, improving the enrichment stability of extracellular vesicles derived from stem cells, reducing the risk of solid-liquid separation residues and coupling agent residues, and solving the problem of balancing enrichment capacity with solid-liquid separation and grafting stability with biosafety. It is suitable for in vitro stem cell culture and extracellular vesicle preparation.

The application discloses a kind of serum-free epidermal melanocyte culture medium and its application, method includes by dissolving adenine, hepatocyte growth factor (HGF), glutamine, retinoic acid, vitamin E, nicotinic acid, sodium selenite, sodium hyaluronate and recombination human type XVII collagen are configured into initial culture medium;Preparation of melanocyte stimulating hormone, endothelin-3, transferrin, triiodothyronine, cholesterol, neuroregulin 1 (NRG1), 3-isobutyl-1-methyl purine (IBMX), dibutyryl cyclic adenosine monophosphate (db-cAMP), cholera toxin, hydrocortisone and recombination human insulin mother liquor;Step three: according to culture and concentration, a certain amount of mother liquor of step two is added to initial culture medium.The culture medium can effectively promote human epidermal melanocyte proliferation, melanin accumulation and help to promote human umbilical cord mesenchymal stem cells into human epidermal melanocyte, provide key advantage for obtaining functional melanocyte with high activity and therapeutic potential.

Novel derivatives of human insulin are described that have binding affinities for the IGF-1 receptor surprisingly comparable to human IGF-1, while having higher affinities for both isoforms of the insulin receptor than human insulin. The novel insulin derivatives have D-histidine or glycine at position B24, the B chain has glycine at the C-terminus at position B31 and tyrosine at position B32, and glutamic or aspartic acid at position B10. The derivatives of the invention can be used particularly for growth and proliferation stimulation in cell cultures or for treatment of neurological disorders as of Alzheimer's disease, Huntington's and Parkinson's diseases, a cognitive loss or symptoms of syndromic autism, since one derivative could mediate both insulin and IGF-1 function.

The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U / mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

The application relates to the field of biotechnology, and discloses a culture medium system for maintaining and directionally inducing pluripotency of embryonic stem cells and application thereof. The culture medium comprises the following components in mass fractions: human insulin: 8-12 parts; tetramethylene diamine: 0.5-0.8 parts; luteinizing hormone: 0.2-0.5 parts; vitamin mixture: 1-2 parts; bovine serum albumin: 2-4 parts; sodium bicarbonate: 0.5-1.0 parts; antibiotic mixture: 0.2-0.4 parts; biotin: 1-2 parts; bone morphogenetic protein: 0.5-1.0 parts; and magnesium ethylenediaminetetraacetate: 0.1-0.2 parts. The application constructs a multi-factor regulation system, combines a signal inhibition, a three-dimensional support and a metabolic regulation module, realizes stable maintenance of pluripotency of embryonic stem cells, significantly improves culture uniformity, structural support and anti-differentiation capacity, and breaks through the technical bottleneck of a traditional system in terms of induction efficiency and stability.